Caralluma Fimbriata — Research Profile

The limited clinical data shows modest appetite reduction (reduced hunger and desire to eat) at 1,000 mg/day ^[1]. A 16-week DBRPCT (n=83) confirmed reduced calorie intake and waist circumference vs placebo ^[3]. The effect is not dramatic but consistent with its traditional use as a famine food. It may help with portion control and snacking but should not be relied upon as a sole weight loss strategy.

Caralluma has weaker evidence than glucomannan (fiber-based satiety) or caffeine (stimulant-based appetite suppression). Its advantage is a different mechanism (pregnane glycosides) and minimal stimulant effects. It could complement other approaches without adding caffeine-related side effects.

Short-term studies (up to 60 days) show a good safety profile. However, long-term safety data is lacking. The plant has been consumed traditionally in India for centuries during food scarcity, suggesting reasonable safety, but formal long-term studies are needed.

Human trials almost exclusively used an encapsulated standardized extract taken as 500 mg twice daily ^[3][6], and no study has compared extract versus whole-plant powder or capsules versus liquid, so no form is proven superior. The standardized extract is simply the only form with human efficacy and tolerability data behind it ^[1].

Evidence is modest and mixed. A systematic review and meta-analysis found it significantly reduced waist circumference (by about 1.59 cm) and waist-to-hip ratio versus placebo, but produced no significant change in body weight, BMI, or measured appetite, leading the authors to conclude it cannot be recommended as a weight-loss supplement or appetite suppressant ^[2]. Individual trials show reduced self-reported hunger and central adiposity ^[1][3], and it eased hyperphagia in children with Prader-Willi syndrome ^[5].

The dose used in nearly all human trials is 1 g/day of standardized extract, typically taken as 500 mg twice daily ^[1][6]. No trial has identified an optimal or higher effective dose, and amounts above 1 g/day have not been tested ^[2].

Trials dosed it as two divided doses across the day rather than a single dose ^[1][6], but no study has directly compared taking it before versus with meals, or morning versus evening. Splitting the 1 g into two doses is the only pattern with trial support; beyond that, optimal timing is not established.

Across the trials that tracked them, the reported adverse effects were gastrointestinal - constipation, diarrhoea and nausea - plus occasional skin rashes ^[2]. Few studies recorded side effects systematically and none characterized their severity, so the overall side-effect profile is not well quantified ^[2].

No dedicated human drug-interaction studies exist, so interactions are not well characterized ^[2]. However, preclinical animal and in vitro research indicates Caralluma fimbriata can lower blood glucose (partly through alpha-amylase and alpha-glucosidase inhibition), so a theoretical additive effect with antidiabetic medications is plausible and monitoring blood sugar is sensible if you take them. The evidence base is currently too thin to confirm or rule out interactions in humans.

It is aimed at overweight adults wanting modest help with appetite and central (waistline) fat, though the overall weight-loss evidence is weak ^[2]. The clearest signal is a reduction in waist circumference in overweight adults ^[1][3], plus eased hyperphagia in children with Prader-Willi syndrome under supervision ^[5]. It is not a proven weight-loss agent and should not replace dietary change and physical activity.

Effects build over weeks, not days. In a controlled trial using 1 g/day, self-reported hunger and waist circumference fell significantly over 60 days ^[1], and an anxiety trial at 1,000 mg/day showed measurable changes by week 4 ^[4], while body-composition benefits were assessed at 16 weeks ^[3]. Plan on roughly 4-8 weeks of consistent use before judging any effect on appetite or waistline.

The longest controlled trials ran only about 16 weeks, so safety and efficacy beyond roughly four months of continuous daily use have not been established ^[3][2]. Within that window it was generally tolerated; the adverse effects reported across trials were constipation, diarrhoea, nausea and rashes, but few studies tracked side effects systematically and none characterized their severity ^[2]. No long-term human studies exist to confirm safety past a few months.

No tolerable upper limit has been defined. Human trials did not exceed 1 g/day, and higher intakes have not been studied, so there is no evidence supporting larger doses ^[1][2]. At standard doses the main dose-related complaints are gastrointestinal, such as nausea, constipation, or diarrhea ^[2].

No rigorous interaction studies exist, so combinations are not well characterized. It has been used alongside diet and exercise in trials without reported problems ^[6]. Preclinical animal and in vitro research suggests Caralluma fimbriata has glucose-lowering potential, so pairing it with other blood-sugar-lowering supplements could theoretically have an additive effect and warrants caution and glucose monitoring. There is no evidence that stacking it with other weight-loss supplements improves results.

Human trials used an encapsulated extract dosed at 1 g/day, typically split as 500 mg twice daily ^[1][6], so choose a product that clearly states the extract and its per-capsule dose (rather than unspecified raw plant powder) and that lets you reach about 1 g/day. No particular brand or standardization method has been validated as superior in the trial literature, so claims of a proprietary edge are not evidence-based. Third-party testing for identity and contaminants is a sensible precaution for any botanical extract.